EN
SINOVAC Launches New Influenza Vaccine Production Facility
Plant will expand worldwide flu vaccine capacity while setting leading standards for quality and sustainability
April 10, 2023, Beijing, China – Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced the start of operations at its new, state-of-the-art influenza vaccine production facility in Beijing recently. The plant, which complies with Chinese Good Manufacturing Practice (GMP) guidelines and utilizes green production processes, enables automated production at scale that expands SINOVAC capacity to meet the growing global demand for high-quality influenza vaccines.
SINOVAC is committed to leveraging digital and intelligent technologies to optimize the vaccine production process and ensure the highest quality. By adopting digital systems and tools, such as the manufacturing execution system (MES), laboratory information management system (LIMS), document management system (DMS), and warehouse management system (WMS), SINOVAC is able to track and monitor each step of the production process, from material procurement to transportation and storage, ensuring complete traceability and transparency.
The new facility features 100% fully automated egg inspection before and after virus inoculation, ensuring each egg is fully viable and healthy. And multiple step purification process ensures the acquisition of high-purity vaccine antigen.
In addition to its advanced technology and strict quality control measures, the plant incorporates recycling practices that promote environmental sustainability. For example, waste embryos are rendered harmless through proper treatment and then reused as fertilizer. The site also features wastewater and exhaust treatment systems in the cultivation area that meet national environmental standards, thus ensuring 100% biological safety. These investments result in a highly efficient production process that minimizes ecological impact.
SINOVAC has the most comprehensive portfolio of influenza vaccines in China, including the H5N1 flu vaccine, Panflu®, and world's first H1N1 flu vaccine, Panfu.1®, as well as China's first preservative-free trivalent influenza vaccine, Anflu®, and quadrivalent influenza vaccine, TetrAnflu®. Outside of China, TetrAnflu® has been approved in Bangladesh and the Dominican Republic for market use.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.